The Shore Capital Reiterates Hold Rating for AstraZeneca plc (AZN)

The Shore Capital Reiterates Hold Rating for AstraZeneca plc (AZN)

Several other equities research analysts have also recently weighed in on AZN. Liberum Capital reissued a hold rating and set a GBX 5,200 ($66.80) price target on shares of AstraZeneca plc in a research report on Monday, January 23rd. Kepler Capital Markets reissued a buy rating and set a GBX 5,000 ($64.23) price target on shares of AstraZeneca plc in a research report on Monday, January 23rd. Investec initiated coverage on shares of AstraZeneca plc in a research report on Monday, January 23rd. They set a hold rating and a GBX 4,600 ($59.09) price target for the company. Deutsche Bank AG restated a buy rating and issued a GBX 6,000 ($77.07) price objective on shares of AstraZeneca plc in a report on Tuesday, January 24th. Finally, Goldman Sachs Group Inc decreased their price objective on shares of AstraZeneca plc from GBX 4,000 ($51.38) to GBX 3,900 ($50.10) and set a sell rating for the company in a report on Tuesday, January 24th. Six analysts have rated the stock with a sell rating, six have assigned a hold rating and nine have issued a buy rating to the company’s stock. AstraZeneca plc has a consensus rating of Hold and an average price target of GBX 5,026.80 ($64.57).

Shore Capital restated their hold rating on shares of AstraZeneca plc (LON:AZN) in a research report sent to investors on Tuesday, May 23rd.

About AstraZeneca plc AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “LSE:AZN”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for AstraZeneca plc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for AstraZeneca plc and related companies with MarketBeat.com’s FREE daily email newsletter.

Related posts

Leave a Comment